No Data
No Data
Wells Fargo Maintains Aerovate(AVTE.US) With Buy Rating, Maintains Target Price $35
Wells Fargo analyst Tiago Fauth maintains $Aerovate(AVTE.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 35.4% and a total a
Wedbush Maintains Aerovate(AVTE.US) With Buy Rating, Maintains Target Price $41
Wedbush analyst Andreas Argyrides maintains $Aerovate(AVTE.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 46.5% and a total
TD Cowen Maintains Aerovate(AVTE.US) With Buy Rating
TD Cowen analyst Joseph Thome maintains $Aerovate(AVTE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.0% and a total average return of 0.0% over the past year.
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)
Aerovate Therapeutics Presents Baseline Data From the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at
Aerovate(AVTE.US) Officer Sells US$215.76K in Common Stock
$Aerovate(AVTE.US)$ Officer NOYES TIMOTHY P sold 10,000 shares of common stock on May 16, 2024 at an average price of $21.5755 for a total value of $215.76K.Source: Announcement What is statement of c